Systematic review of hypofractionated radiation therapy for prostate cancer

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 728-736

  Zaorsky, Nicholas G ^a   Ohri, Nitin ^a   Showalter, Timothy N ^b   Dicker, Adam P ^a   Den, Robert B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Hypofractionation; Prostate cancer; Quality of life; Radiotherapy; Toxicity

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; DISTANT METASTASIS; HEALTH CARE QUALITY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; CANCER STAGING; CLINICAL TRIAL (TOPIC); HYPOFRACTIONATION; MALE; META ANALYSIS; PATHOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; RADIOTHERAPY; TOXICITY; TREATMENT OUTCOME;

HYPOFRACTIONATION; PROSTATE CANCER; QUALITY OF LIFE; RADIOTHERAPY; TOXICITY;

CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84881557290     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.008     Document Type: Review

References (62)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
3. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-988.
4. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239.
5. Zietman A.L., Bae K., Slater J.D., et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therpay in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American College of Radiology 95-09. J Clin Oncol 2010, 28(7):1106-1111.
6. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8(6):475-487.
7. Zagars G.K., von Eschenbach A.C., Johnson D.E., Oswald M.J. The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988, 14(4):701-709.
8. Wang J.Z., Li X.A. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 2005, 61(1):220-227.
9. Fowler J.F., Ritter M.A., Chappell R.J., Brenner D.J. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 56(4):1093-1104.
10. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52(1):6-13.
11. Holmboe E.S., Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000, 15(10):694-701.
12. Sethukavalan P., Cheung P., Tang C.I., et al. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy. Can J Urol 2012, 19(2):6165-6169.
13. Parthan A., Pruttivarasin N., Davies D., et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol 2012, 2:81. 10.3389/fonc.2012.00081.
14. Perez C.A., Kobeissi B., Smith B.D., et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys 1993, 25(5):895-906.
15. Lievens Y., van den Bogaert W., Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57(2):522-535.
16. Norlund A. Costs of radiotherapy. Acta Oncol 2003, 42(5-6):411-415.
17. Van de Werf E., Lievens Y., Verstraete J., Pauwels K., Van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol 2009, 93(1):137-140.
18. Kesteloot K., Lievens Y., van der Schueren E. Improved management of radiotherapy departments through accurate cost data. Radiother Oncol 2000, 55(3):251-262.
19. Zaorsky N.G., Studenski M.T., Dicker A.P., Gomella L., Den R.B. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?. Cancer Treat Rev. 2013, 39(3):212-218. 10.1016/j.ctrv.2012.10.003.
20. Button M.R., Staffurth J.N. Clinical application of image-guided radiotherapy in bladder and prostate cancer. Clin Oncol (R Coll Radiol) 2010, 22(8):698-706.
21. Lukka H., Hayter C., Julian J.A., et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005, 23(25):6132-6138.
22. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006, 66(4):1072-1083.
23. Yeoh E.E., Botten R.J., Butters J., et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011, 81(5):1271-1278.
24. Arcangeli G., Saracino B., Gomellini S., et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 78(1):11-18.
25. Arcangeli G., Fowler J., Gomellini S., et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79(4):1013-1021.
26. Arcangeli S., Strigari L., Gomellini S., et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84(5):1172-1178.
27. Pollack A., Hanlon A.L., Horwitz E.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006, 64(2):518-526.
28. Pollack A., Walker G., Buyyounouski M., et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81(2):S1.
29. Kuban D.A., Nogueras-Gonzalez G.M., Hamblin L., et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010, 78(3):S58-S59.
30. Kupelian P.A., Willoughby T.R., Reddy C.A., Klein E.A., Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70Gy at 2.5Gy per fraction) for localized prostate cancer: cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(5):1424-1430.
31. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13(1):43-54.
32. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50(4):1021-1031.
33. Hanks G.E. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr 1988, 7:75-84.
34. Duncan W., Warde P., Catton C.N., et al. Carcinoma of the prostate: results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 1993, 26(2):203-210.
35. Read G., Pointon R.C. Retrospective study of radiotherapy in early carcinoma of the prostate. Br J Urol 1989, 63(2):191-195.
36. Kearsley J.H. High-dose radiotherapy for localized prostatic cancer. An analysis of treatment results and early complications. Med J Aust 1986, 144(12):624-628.
37. Preston C.I., Duncan W., Kerr G.R. Radical treatment of prostatic carcinoma by megavoltage X-ray therapy. Clin Radiol 1986, 37(5):473-477.
38. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37(5):1035-1041.
39. Abramowitz M.C., Li T., Buyyounouski M.K., et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008, 112(1):55-60.
40. Buyyounouski M.K., Hanlon A.L., Eisenberg D.F., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2005, 63(5):1455-1462.
41. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998, 41(2):267-272.
42. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002, 52(3):704-711.
43. Miles E.F., Lee W.R. Hypofractionation for prostate cancer: a critical review. Semin Radiat Oncol 2008, 18(1):41-47.
44. McBride S.M., Wong D.S., Dombrowski J.J., et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012, 118(15):3681-3690.
45. Madsen B.L., Hsi R.A., Pham H.T., et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007, 67(4):1099-1105.
46. Denham J.W., O'Brien P.C., Dunstan R.H., et al. Is there more than one late radiation proctitis syndrome?. Radiother Oncol 1999, 51(1):43-53.
47. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177(6):2106-2131.
48. Khor L.Y., Moughan J., Al-Saleem T., et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res 2007, 13(12):3585-3590.
49. Pollack A., Cowen D., Troncoso P., et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003, 97(7):1630-1638.
50. Zhou J.R., Yu L., Zerbini L.F., Libermann T.A., Blackburn G.L. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 2004, 110(6):800-806.
51. Pollack A., Cowen D., Troncoso P., et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Cancer 2003, 97(7):1630-1638.
52. Bantis A., Giannopoulos A., Gonidi M., et al. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 2004, 15(1):25-31.
53. Roach M., Waldman F., Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009, 115(Suppl. 13):3112-3120.
54. Zwahlen D.R., Lang S., Hrbacek J., et al. The use of photon beams of a flattening filter-free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83(5):1655-1660.
55. Klayton T., Price R., Buyyounouski M.K., et al. Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys 2012, 84(1):130-136.
56. Zelefsky M.J., Kollmeier M., Cox B., et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84(1):125-129.
57. de Crevoisier R., Tucker S.L., Dong L., et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62(4):965-973.
58. Heemsbergen W.D., Hoogeman M.S., Witte M.G., et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68GY versus 78Gy. Int J Radiat Oncol Biol Phys 2007, 67(5):1418-1424.
59. Song W.Y., Schaly B., Bauman G., Battista J.J., Van Dyk J. Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis. Int J Radiat Oncol Biol Phys 2006, 64(1):289-300.
60. Sheets N.C., Goldin G.H., Meyer A.M., et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 2012, 307(15):1611-1620.
61. Coen J.J., Paly J.J., Niemierko A., et al. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82(2):e201-e209.
62. Vogelius I.R., Bentzen S.M. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. Int J Radiat Oncol Biol Phys 2013, 85(1):89-94.